The Claim
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already on statin therapy, daily oral administration of 20 mg enlicitide decanoate for 24 weeks results in a mean reduction of low-density lipoprotein cholesterol (LDL-C) by 58.2%, compared to a 2.6% change with placebo, yielding a statistically significant between-group difference of −59.4% (95% CI: −65.6% to −53.2%; p < 0.001), indicating that enlicitide provides additional LDL-C lowering beyond statins.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with a genetic cholesterol problem who are already on cholesterol pills, taking a new drug called enlicitide every day for 6 months might slash their bad cholesterol way more than just the usual treatment alone.
See the scientific wording
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already taking statins, daily treatment with 20 mg of oral enlicitide decanoate for 24 weeks reduces low-density lipoprotein cholesterol (LDL-C) levels by a mean of 58.2% compared to a 2.6% change with placebo, representing a between-group difference of −59.4% (95% CI: −65.6% to −53.2%), which is statistically significant (p < 0.001). This suggests enlicitide may help high-risk patients achieve greater LDL-C lowering beyond statin therapy alone.
What the research says
1 studyThe study tested the exact same pill, dose, and patient group described in the claim, and found it dramatically lowered bad cholesterol compared to a placebo.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.